Overview

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

Status:
Completed
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of camrelizumab plus apatinib in patients with high-risk chemo-refractory or relapsed GTN.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Apatinib